Fig. 6: Breast tumour cells are resistant to paclitaxel but sensitive to metformin in an obese setting. | npj Breast Cancer

Fig. 6: Breast tumour cells are resistant to paclitaxel but sensitive to metformin in an obese setting.

From: Development and characterisation of a novel 3D in vitro model of obesity-associated breast cancer as a tool for drug testing

Fig. 6

Organotypic cultures were treated for 48 h with one of four therapeutic compounds: 10 µM paclitaxel (PCX), 10 µM tamoxifen (TMX), 50 µM doxorubicin (DOX), 25 µM metformin (MET), or a DMSO control (CTR). Cell viability was determined via CellTiter-Glo® 3D assay, according to manufacturer’s instructions, in breast tumour organotypic a co-, b quadra- or c penta-cultures containing either MA or HA. Cell viability was determined by converting luminescence values into cell viability by normalising drug-treated cultures to the control cultures. d Summary of paclitaxel and metformin treatment in MCF-7 or T47D organotypics across different co-culture conditions. Data were obtained from three independent experiments, with triplicate organotypic samples per treatment condition. Statistical significance between groups was assessed using an ordinary One-Way ANOVA with Dunnett’s or Kruskal–Wallis comparison test. ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05. All other comparisons were non-significant (P > 0.05).

Back to article page